Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Gynecologic Cancer 1Digestive System Diseases 1Carcinoma, Hepatocellular 1

Interventions

durvalumab 18Bevacizumab 17atezolizumab 13lenvatinib 10Magnetic Resonance Spectroscopy 10tremelimumab 8Nivolumab 8pembrolizumab 7Sorafenib 6Specimen Handling 5camrelizumab 4cabozantinib 4Immunoglobulin G 4Disulfides 4sintilimab 3apatinib 3X-Rays 3Radiotherapy 3Radiofrequency Ablation 3Radiation 3Hepatectomy 3E-7386 3Doxorubicin 3Cyclophosphamide 3tislelizumab 2relatlimab 2dostarlimab 2budigalimab 2Standard of Care 2Simvastatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Hepatocellular × gadobutrol × Clear all
NCT02156739 2025-12-22

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

M.D. Anderson Cancer Center

Phase NA Active not recruiting
100 enrolled
Gastrointestinal

Digestive System Diseases, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡